Unraveling Melorheostosis: Insights into Clinical Features, Diagnosis, and Treatment

Overview

Journal JBMR Plus

Publisher Oxford University Press

Date 2025 Jan 8

PMID 39776616

Authors

Timothy Bhattacharyya

Affiliations

Soon will be listed here.

Abstract

Melorheostosis is a rare bone disease characterized by abundant bone formation with a characteristic radiographic appearance that resembles "dripping candle wax." Recent data have shown that the majority of cases are due to somatic activating mutations in bone. Melorheostosis has several clinical and radiographic presentations, which are now known to be caused by different somatic mutations such as , , , and . This review provides a comprehensive look at the clinical features, diagnostic approaches, and current treatment options for melorheostosis, alongside future research directions aimed at improving patient outcomes.

References

Jha S, Fratzl-Zelman N, Roschger P, Papadakis G, Cowen E, Kang H . Distinct Clinical and Pathological Features of Melorheostosis Associated With Somatic MAP2K1 Mutations. J Bone Miner Res. 2018; 34(1):145-156. PMC: 7577747. DOI: 10.1002/jbmr.3577. View

Fryns J . Melorheostosis and somatic mosaicism. Am J Med Genet. 1995; 58(2):199. DOI: 10.1002/ajmg.1320580221. View

Mumm S, Wenkert D, Zhang X, McAlister W, Mier R, Whyte M . Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J Bone Miner Res. 2006; 22(2):243-50. DOI: 10.1359/jbmr.061102. View

Hurley-Novatny A, Allbritton-King J, Jha S, Cowen E, Colbert R, Navid F . Fibroblasts from Patients with Melorheostosis Promote Angiogenesis in Healthy Endothelial Cells through Secreted Factors. J Invest Dermatol. 2022; 142(9):2406-2414.e5. PMC: 9388700. DOI: 10.1016/j.jid.2022.02.006. View

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

WYNNE-DAVIES R, Gormley J . The prevalence of skeletal dysplasias. An estimate of their minimum frequency and the number of patients requiring orthopaedic care. J Bone Joint Surg Br. 1985; 67(1):133-7. DOI: 10.1302/0301-620X.67B1.3155744. View

Fick C, Fratzl-Zelman N, Roschger P, Klaushofer K, Jha S, Marini J . Melorheostosis: A Clinical, Pathologic, and Radiologic Case Series. Am J Surg Pathol. 2019; 43(11):1554-1559. PMC: 7832124. DOI: 10.1097/PAS.0000000000001310. View

De Ridder R, Boudin E, Zillikens M, Ibrahim J, van der Eerden B, Van Hul W . A multi-omics approach expands the mutational spectrum of MAP2K1-related melorheostosis. Bone. 2020; 137:115406. DOI: 10.1016/j.bone.2020.115406. View

Kotwal A, Clarke B . Melorheostosis: a Rare Sclerosing Bone Dysplasia. Curr Osteoporos Rep. 2017; 15(4):335-342. DOI: 10.1007/s11914-017-0375-y. View

10.

Fratzl-Zelman N, Roschger P, Kang H, Jha S, Roschger A, Blouin S . Melorheostotic Bone Lesions Caused by Somatic Mutations in MAP2K1 Have Deteriorated Microarchitecture and Periosteal Reaction. J Bone Miner Res. 2019; 34(5):883-895. PMC: 8302214. DOI: 10.1002/jbmr.3656. View

11.

Hurley-Novatny A, Karantanas A, Papadakis G, Bhattacharyya T, Jha S . Cross-Sectional Imaging Useful in Melorheostosis. JBMR Plus. 2021; 5(4):e10472. PMC: 8046147. DOI: 10.1002/jbm4.10472. View

12.

Jha S, Cowen E, Lehky T, Alter K, Flynn L, Reynolds J . Clinical Evaluation of Melorheostosis in the Context of a Natural History Clinical Study. JBMR Plus. 2019; 3(8):e10214. PMC: 6715778. DOI: 10.1002/jbm4.10214. View

13.

Kang H, Jha S, Deng Z, Fratzl-Zelman N, Cabral W, Ivovic A . Somatic activating mutations in MAP2K1 cause melorheostosis. Nat Commun. 2018; 9(1):1390. PMC: 5895796. DOI: 10.1038/s41467-018-03720-z. View

14.

Byberg S, Abrahamsen B, Kassem M, Ralston S, Schwarz P . Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report. J Med Case Rep. 2018; 12(1):278. PMC: 6158818. DOI: 10.1186/s13256-018-1820-y. View

15.

Whyte M, Griffith M, Trani L, Mumm S, Gottesman G, McAlister W . Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone. 2017; 101:145-155. PMC: 5518630. DOI: 10.1016/j.bone.2017.04.010. View

16.

Kang H, Jha S, Ivovic A, Fratzl-Zelman N, Deng Z, Mitra A . Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway. J Exp Med. 2020; 217(5). PMC: 7201932. DOI: 10.1084/jem.20191499. View

17.

Freyschmidt J . Melorheostosis: a review of 23 cases. Eur Radiol. 2001; 11(3):474-9. DOI: 10.1007/s003300000562. View

18.

Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonk P, Costa T . Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet. 2004; 36(11):1213-8. DOI: 10.1038/ng1453. View

19.

Jha S, Laucis N, Kim L, Malayeri A, Dasgupta A, Papadakis G . CT analysis of anatomical distribution of melorheostosis challenges the sclerotome hypothesis. Bone. 2018; 117:31-36. PMC: 11060331. DOI: 10.1016/j.bone.2018.09.005. View

20.

Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S . Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. View